Q
Quanta Therapeutics
Innovative oncology therapeutics targeting Ras-driven cancers with precision medicine
About Quanta Therapeutics
Quanta Therapeutics Inc., headquartered in South San Francisco, CA, is a biopharmaceutical company that specializes in the development of allosteric inhibitors for RAS-driven cancers. These are a type of cancer that are difficult to treat, including lung, colon, and pancreatic cancer. Allosteric inhibitors are a type of drug that changes the activity of a protein by binding to it at a site other than its active site. In this case, Quanta is developing drugs to target RAS mutations, which are often found in these types of cancers.
Read full description
The company's business model revolves around the development and commercialization of these drugs. They are using their deep understanding of biology, unique protein detection technology, and medicinal chemistry expertise to develop oral small molecules that could potentially lead the next wave of innovation in KRAS therapy.
Quanta's clients are primarily patients suffering from these types of cancers. The market they operate in is the biopharmaceutical industry, specifically the segment focused on cancer treatment. They make money by developing and selling their drugs to healthcare providers who then administer them to patients.
The company is led by a team of experienced professionals who are leaders in RAS biology and expert medicinal chemists. They have a strong track record, having contributed to the discovery, development, approval, and launch of multiple biopharmaceutical medicines.
At a glance
- Status
- Operational
- Founded
- 2018
- Headquarters
- South San Francisco, United States
- Employees
- 35
- Open positions
- None listed
- Dealroom signal
- 66.0/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Precision Medicine, Spinout, Biotech and Pharma, proteomics, DT and LS, science-based
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES DOther financing | May 2023 | $51M | $300M | Abbvie Biotech Ventures · Vida Ventures · Sofinnova Investments · Surveyor Capital | ↗ |
| SERIES COther financing | Oct 2021 | $60M | $240M | Abbvie Biotech Ventures · Longitude Capital · Vida Ventures · Sofinnova Investments | — |
Growth signals
Latest recorded traffic for Quanta Therapeutics is 3.2K monthly website visits, up 33.3% over the last three months. Quanta Therapeutics's team declined 12.5% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
Abbvie Biotech Ventures
Vida Ventures
Sofinnova Investments
Logos Capital
Series B and later6 investors entered at this stage
Longitude Capital
Surveyor Capital
BVF Partners
Avidity Partners- GIGC&H Investments
- WIWS Investment
Other known investors1 additional known investor
University of California, San Francisco
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Quanta Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Quanta Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.